MD Communications Group
  • Home
  • Services
  • Areas of Expertise
  • Qualifications
  • Clients
  • Contact

       Women's Health

                   At a glance...
  • Menopause, vasomotor symptoms, female sexual dysfunction, instrument validation, infertility, osteoporosis, overactive bladder
  • Ultra-low-dose estrogen, transdermal  testosterone gel, progesterone, bisphosphonates, denosumab, fertility products, parathyroid hormone,  antimuscarinics

Publications

“Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen” (review)

“Post-menopausal hormone therapy -- improving the risk-benefit ratio with ultra-low doses of estrogen” (review)

“Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women” (review)

“Validation of the Inventory of Sexual Events and Desire (ISED) diary in female hypoactive sexual desire disorder”

Comprehensive literature analysis of female sexual dysfunction and safety/ efficacy review of the testosterone patch

“Crinone (progesterone gel) 8% in assisted reproductive technology” (clinical monograph)

“Cetrotide (GnRH antagonist)” (clinical monograph)

“Disorders associated with acute rapid and severe bone loss: implications for anabolic therapy” (slide presentation)

“Ibandronate sodium in osteoporosis” (competitive backgrounder and slides)

“Denosumab in osteoporosis” (competitive backgrounder and slides)

“Comparison of efficacy and safety endpoints of antimuscrinic agents used for treatment of OAB” (slide presentation)

Comprehensive literature search and summary on safety/efficacy/economics of antimuscarinics in overactive bladder


Back to Areas of Expertise
            
phone/fax: (760) 448-6668 | email:info@mdcommgroup.com